Wall Street Zen Upgrades uniQure (NASDAQ:QURE) to Hold

uniQure (NASDAQ:QURE) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Several other equities research analysts have also issued reports on QURE. Wells Fargo & Company lowered their price target on shares of uniQure from $80.00 to $60.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 12th. HC Wainwright lowered their target price on uniQure from $110.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, November 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of uniQure in a report on Wednesday, October 8th. Mizuho reduced their price target on uniQure from $60.00 to $33.00 and set an “outperform” rating for the company in a research report on Monday, December 8th. Finally, Benchmark reaffirmed a “buy” rating on shares of uniQure in a research report on Tuesday, November 4th. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $60.82.

uniQure Stock Down 2.3%

Shares of uniQure stock opened at $23.39 on Friday. The firm has a market cap of $1.46 billion, a PE ratio of -5.33 and a beta of 0.68. The business’s 50 day simple moving average is $30.01 and its 200 day simple moving average is $27.13. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12. uniQure has a 52-week low of $7.76 and a 52-week high of $71.50.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.53). uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%.The business had revenue of $3.70 million for the quarter, compared to the consensus estimate of $4.46 million. On average, analysts predict that uniQure will post -3.75 earnings per share for the current fiscal year.

Insider Activity at uniQure

In other uniQure news, Director Jack Kaye sold 38,810 shares of uniQure stock in a transaction on Tuesday, November 4th. The shares were sold at an average price of $30.34, for a total transaction of $1,177,495.40. Following the completion of the transaction, the director directly owned 20,439 shares of the company’s stock, valued at $620,119.26. The trade was a 65.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Robert Gut sold 31,434 shares of the company’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $27.26, for a total transaction of $856,890.84. Following the completion of the transaction, the director owned 40,145 shares in the company, valued at approximately $1,094,352.70. This represents a 43.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 4.79% of the company’s stock.

Institutional Trading of uniQure

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Jefferies Financial Group Inc. bought a new position in uniQure in the 2nd quarter valued at about $29,217,000. JPMorgan Chase & Co. grew its position in shares of uniQure by 471.7% in the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock valued at $25,199,000 after purchasing an additional 1,491,486 shares during the last quarter. Fred Alger Management LLC bought a new position in shares of uniQure during the third quarter worth approximately $75,320,000. Sofinnova Investments Inc. lifted its holdings in uniQure by 185.5% during the 2nd quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company’s stock worth $21,723,000 after purchasing an additional 1,012,585 shares during the last quarter. Finally, Avoro Capital Advisors LLC lifted its holdings in uniQure by 22.6% during the 3rd quarter. Avoro Capital Advisors LLC now owns 4,444,444 shares of the biotechnology company’s stock worth $259,422,000 after purchasing an additional 819,444 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.